55249
document
Oral magnesium supplementation in children with cystic fibrosis improves clinical and functional variables : a double-blind , randomized , placebo-controlled crossover trial . BACKGROUND Magnesium is one of the most important minerals in the body . Although some studies reported that patients with cystic fibrosis ( CF ) lack magnesium , no international study has assessed the importance of oral magnesium supplementation in CF patients . OBJECTIVE We prospectively investigated the long-term effect of oral magnesium supplementation on respiratory muscle strength by using manuvacuometry and the Shwachman-Kulczycki ( SK ) score among children and adolescents with CF . DESIGN This double-blind , randomized , placebo-controlled crossover study included 44 CF patients ( aged 7-19 y ; 20 males ) who were randomly assigned to receive magnesium ( n = 22 ; 300 mg/d ) or placebo ( n = 22 ) for 8 wk with a 4-wk washout period between trials . All patients were undergoing conventional treatment of CF . The experimental protocol included clinical evaluation , assessment of urinary concentration of magnesium , and manuvacuometric measurements [ maximal inspiratory pressure ( MIP ) and maximal expiratory pressure ( MEP ) ] . MIP was the primary outcome . RESULTS Urinary magnesium increased after the administration of magnesium ( change : 36.38 mg/d after magnesium compared with 0.72 mg/d after placebo ; P < 0.001 ) . Moreover , MIP and MEP significantly improved only after magnesium administration ( change in MIP : 11 % predicted after magnesium compared with 0.5 % predicted after placebo ; change in MEP : 11.9 % predicted after magnesium compared with 0.8 % predicted after placebo ; P < 0.001 for both ) . Magnesium administration had a beneficial effect on clinical variables assessed by the SK score ( change : 4.48 points after magnesium compared with -1.30 points after placebo ; P < 0.001 ) . CONCLUSION Oral magnesium supplementation helped improve both the SK score and respiratory muscle strength in pediatric patients with CF .
55250
Intervention_Pharmacological
magnesium supplementation
55251
Intervention_Pharmacological
magnesium
55252
Intervention_Pharmacological
magnesium
55253
Intervention_Control
placebo
55254
Intervention_Pharmacological
magnesium
55255
Intervention_Pharmacological
magnesium
55256
Outcome_Physical
respiratory muscle strength
55257
Outcome_Physical
Shwachman-Kulczycki ( SK ) score
55258
Outcome_Physical
maximal inspiratory pressure ( MIP )
55259
Outcome_Physical
maximal expiratory pressure ( MEP )
55260
Outcome_Physical
MIP
55261
Outcome_Physical
Urinary magnesium
55262
Outcome_Physical
MIP
55263
Outcome_Physical
MEP
55264
Outcome_Physical
SK score
55265
Outcome_Other
SK score and respiratory muscle strength
55266
Participant_Age
children
55267
Participant_Condition
cystic fibrosis
55268
Participant_Age
children and adolescents
55269
Participant_Condition
CF
55270
Participant_Sample-size
44
55271
Participant_Age
aged 7-19 y
55272
Participant_Sex
20 males
55273
Participant_Sample-size
22
55274
Participant_Sample-size
22